Next Phase Newsletter

A venture capital firm based in Switzerland raised a new fund in 2016. The firm generally makes equity investments into internet and health tech companies at seed and early stages. The typical investment size ranges from €0.2 million to € 2 million. The firm plans to make 15-20 investments in the next 3 years and it will invest in companies based in Europe with a focus on Switzerland and Germany.

The firm is currently looking for new opportunities in the area of platform technologies, diagnostics, digital health etc. The firm focuses on companies developing biotech platforms, research tools and nutrition in preclinical and clinical stages. The firm will not invest in drug development companies or medical device companies. In the past, the firm was active in companies developing proteomics platform technology, 3D micro tissues technology, diagnostic services, vaccines, and technology platform to develop virus envelopes.

The firm typically seeks to invest in private companies with convincing founders or managers. The firm will consider pre-revenue companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A $150 million venture capital fund managed on behalf of a not-for-profit health system makes direct investments in innovative healthcare companies. Typical equity allocations range from $5-8 million over the life of a company. The firm typically co-invests with other VC funds but is also open to leading in a financing round. The firm is looking primarily for opportunities across the US, and the firm would consider international companies with strong US advocacy and technology that can be deployed to the US market.

The firm is looking for innovative medical technologies that are in line with the organization’s mission, improve quality and convenience, lower cost and improve health outcomes. Examples may include patient management systems for healthcare providers, home care systems, or monitoring devices for chronic disease management. The firm typically works with mature companies with revenue, consumer traction, or some validation on their technology.

The firm is looking for solid management teams that show track records of success. The firm provides healthcare system expertise to portfolio companies to refine existing solutions, while expanding their adoption within and beyond its healthcare system.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A holding company with offices in China and the USA aims to serve human healthcare and technological development through high-tech investment and real estate investment. Through its investment arm the firm makes venture investments in healthcare. Typical allocations range from US$1-10 million in companies from Seed to Series B stages. The firm is open to leading or following in a round. The firm is looking for opportunities from US and Canada that have a China angle.

Within healthcare, the firm considers biopharmaceuticals, medical devices, diagnostics, and AR/VR/AI innovations in healthcare. The firm is focused on diseases with large market potential including oncology, infectious disease, diabetes, CNS, and cardiovascular diseases. The firm is opportunistic in terms of stage of development and typically participates in Seed to Series B rounds.

The firm is seeking innovative products and can aid with management, operations, and registration. Leveraging its resources in China, the firm can facilitate distribution in the China market. However, distribution rights are not a requirement for investment.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in China has over $2 billion in total managed assets in the areas of healthcare, technology and internet, and clean tech.  The firm invests from both a USD fund and an RMB fund, and is raising a new US fund in 2017.  The firm has invested in more than 50 healthcare companies, that span most sectors of life sciences from pharmaceuticals and medical devices to healthcare IT, diagnostics and select healthcare services. The firm intends to lead, co-lead, or co-invest in US-based private companies with equity investments ranging from $3 to $12 million.

The firm is open to many sectors in the life science space – biotech therapeutics, medical devices, diagnostics, and healthcare IT. The firm is most interested in breakthrough products and technologies that address a large unmet need. The firm seeks investments in 510K devices and we will invest in devices in the PMA pathway depending on stage, preferably clinical or later. In therapeutics, the firm is modality-agnostic, but generally seeking opportunities that are past the pre-clinical stage. The firm is also interested in enabling technologies for drug discovery and development, and other healthcare-related technologies in the “digital-health” space.

The firm is seeking to invest in companies with novel ideas and technology and experienced and passionate management. Given the firm’s slogan of “inspiring people with the wisdom to succeed with diligence”, The firm’s team is “hands-on” and typically assumes a board seat after an investment.  Investments in US companies are expected to have upside opportunities in China, and can leverage our China network and expertise.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A chemical and polymer manufacturer is vigorously looking to expand its business into life sciences and seeking for inorganic growth vehicles through strategic investments and acquisitions that reinforce the company’s core competencies.

The company is interested in CDMOs for the biologics field and CRO to support new drug discovery process of pharmaceutical industry.  In addition to this, the firm is looking for disruptive technologies in the fields of precision medicine, stem cell biology & cell-based medicine, Microbiome, designed medical devices and In Vitro Diagnostics.

As for CDMO, startups which have unique value proposition for the pharmaceutical industry are of interest. Regarding CROs, the firm is interested in companies based in Europe or North America with positive operating income. For other technologies, the firm would like to contact startups with at least proof of concept and strong IP. The firm is interested in co-development of these technologies, co-distribution of the product offerings and sharing of profit based on the contribution from each player.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A publicly traded pharma corporation based in China is actively pursuing strategic partnerships with other pharmaceutical companies, natural product producers, universities, hospitals and researchers and developers. The firm considers a board range of strategies including investment, joint venture, acquisition, licensing, and development funding. The firm is looking for opportunities in North America and Europe.

The firm is looking for strategic partnerships in prescription drugs, nutraceuticals, and digital health. Other sectors of interest include healthcare services, children’s health education, and senior care. The firm is open to products at all development stages. Within biopharmaceuticals, the firm takes an opportunistic approach to small molecules, biologics, and other modalities. Within digital health, the firm is looking for products that are complimentary to its pipeline.

The firm is looking to build collaborative partnerships with experienced teams in key strategic sectors. The firm can provide US regulatory expertise, global operation, and distribution channels and clinical trial sites across China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A China-based publicly listed enterprise specialized in blood purification is seeking to collaborate with early stage businesses with advanced technologies that are a strategic fit for its product pipeline. Equity investment size can be flexible but typically ranges from US$0.5-5 million. The firm can also consider collaborative research, licensing, and merger and acquisition. The firm is looking for new opportunities globally with a focus on the US.

The firm is interested in medical devices in the hematology, liver diseases, and cardiovascular diseases fields. The firm prefers post-prototype products with preclinical and clinical validation. Products should have a strategic angle with the firm’s pipeline of products.

The firm is looking for experienced management teams with sector expertise. The firm is interested in distribution rights in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com